Pinkerton Nathalie M, Zhang Stacey W, Youngblood Richard L, Gao Dayuan, Li Shike, Benson Bryan R, Anthony John, Stone Howard A, Sinko Patrick J, Prud'homme Robert K
Department of Chemical and Biological Engineering, Princeton University , Princeton, New Jersey 08544, United States.
Biomacromolecules. 2014 Jan 13;15(1):252-61. doi: 10.1021/bm4015232. Epub 2013 Dec 26.
The formation of 10-40 μm composite gel microparticles (CGMPs) comprised of ∼100 nm drug containing nanoparticles (NPs) in a poly(ethylene glycol) (PEG) gel matrix is described. The CGMP particles enable targeting to the lung by filtration from the venous circulation. UV radical polymerization and Michael addition polymerization reactions are compared as approaches to form the PEG matrix. A fluorescent dye in the solid core of the NP was used to investigate the effect of reaction chemistry on the integrity of encapsulated species. When formed via UV radical polymerization, the fluorescence signal from the NPs indicated degradation of the encapsulated species by radical attack. The degradation decreased fluorescence by 90% over 15 min of UV exposure. When formed via Michael addition polymerization, the fluorescence was maintained. Emulsion processing using controlled shear stress enabled control of droplet size with narrow polydispersity. To allow for emulsion processing, the gelation rate was delayed by adjusting the solution pH. At a pH = 5.4, the gelation occurred at 3.5 h. The modulus of the gels was tuned over the range of 5 to 50 kPa by changing the polymer concentration between 20 and 70 vol %. NP aggregation during polymerization, driven by depletion forces, was controlled by the reaction kinetics. The ester bonds in the gel network enabled CGMP degradation. The gel modulus decreased by 50% over 27 days, followed by complete gel degradation after 55 days. This permits ultimate clearance of the CGMPs from the lungs. The demonstration of uniform delivery of 15.8 ± 2.6 μm CGMPs to the lungs of mice, with no deposition in other organs, is shown, and indicates the ability to concentrate therapeutics in the lung while avoiding off-target toxic exposure.
本文描述了由聚乙二醇(PEG)凝胶基质中约100 nm含药纳米颗粒(NP)组成的10 - 40 μm复合凝胶微粒(CGMP)的形成过程。CGMP颗粒可通过静脉循环过滤实现肺部靶向。比较了紫外自由基聚合反应和迈克尔加成聚合反应作为形成PEG基质的方法。利用NP固体核心中的荧光染料研究反应化学对包封物质完整性的影响。当通过紫外自由基聚合形成时,NP发出的荧光信号表明包封物质受到自由基攻击而降解。在15分钟的紫外线照射下,降解使荧光降低了90%。当通过迈克尔加成聚合形成时,荧光得以保持。使用可控剪切应力的乳液加工方法能够控制液滴尺寸,使其具有窄的多分散性。为了实现乳液加工,通过调节溶液pH来延迟凝胶化速率。在pH = 5.4时,凝胶化在3.5小时发生。通过将聚合物浓度在20%至70%(体积)之间变化,可将凝胶的模量调整到5至50 kPa的范围。聚合过程中由排空力驱动的NP聚集可通过反应动力学进行控制。凝胶网络中的酯键使CGMP能够降解。凝胶模量在27天内下降了50%,随后在55天后凝胶完全降解。这使得CGMP最终能够从肺部清除。结果表明,15.8±2.6 μm的CGMP能够均匀地递送至小鼠肺部,且在其他器官中无沉积,这表明其能够在肺部集中治疗药物,同时避免非靶向毒性暴露。